Patent US6539364B2 successfully refreshed from Google Patents.
US5540931A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
Assignee: Individual
•
Filing: 1994-06-24
•
Granted: 1996-07-30
•
Expires: 2014-06-24
Abstract
Abstract The present invention provides methods and formulations for site-specific immune suppression of immune/inflammatory responses with localized or topical application of immunosuppressants including cyclosporines, rapamycins (RPM), or combinations of immunosuppressants and anti-inflammatory compounds. Methods for the use of said formulations to effect site-specific immune suppression of local inflammatory/immune responses in mammalian tissue and for treatment of autoimmune, T-cell mediated immune disease, inflammatory conditions, inhibition of contact hypersensitivity, and for producing prolonged skin allograft survival, and wound healing are presented. In addition, methods for use of said formulations--in tandem with systemic applications of immunosuppressant such as cyclosporine or without same--are presented. The present invention also relates to alternative formulations and delivery systems for the efficacious treatment of the aforementioned conditions.
Inventors
- 👤 Charles W. Hewitt
- 👤 Kirby S. Black
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:33
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/45; A61K31/4523; A61K31/4525; A61K31/495; A61K31/505; A61K31/519; A61K31/70; A61K31/7042; A61K31/7052; A61K31/706; A61K31/74; A61K31/765; A61K31/77; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61K38/16; A61K38/17; A61K38/177; A61K38/1774; A61K45/00; A61K45/06; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K47/26; A61K47/44
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
29 words
A pharmaceutical composition comprising in approximate amounts by weight: a. 5-60% anhydrous lanolin; b. 5-80% jojoba oil; c. 5-80% olive oil; d. 0.2-20% polysorbate 80; and e. 0.2-25% cyclosporine.
Claim 2
Dependent Claim
29 words
A pharmaceutical composition comprising in approximate amounts by weight: a. 5-60% anhydrous lanolin; b. 5-80% jojoba oil; c. 5-80% olive oil; d. 0.2-20% polysorbate 80; and e. 0.2-25% cyclosporine.
Claim 3
Dependent Claim
29 words
A pharmaceutical composition comprising in approximate amounts by weight: a. 5-60% anhydrous lanolin; b. 5-80% mineral oil; c. 5-80% olive oil; d. 0.2-20% polysorbate 80; and e. 0.2-25% cyclosporine.
Claim 4
Dependent Claim
29 words
A pharmaceutical composition comprising in approximate amounts by weight: a. 5-60% anhydrous lanolin; b. 5-80% mineral oil; c. 5-80% olive oil; d. 0.2-20% polysorbate 80; and e. 0.2-25% cyclosporine.
Claim 5
Dependent Claim
29 words
A pharmaceutical composition comprising in approximate amounts by weight: a. 5-60% anhydrous lanolin; b. 5-80% white petrolatum; c. 5-80% olive oil; d. 0.2-20% polysorbate 80; and e. 0.2-25% cyclosporine.
Claim 6
Dependent Claim
29 words
A pharmaceutical composition comprising in approximate amounts by weight: a. 5-60% anhydrous lanolin; b. 5-80% white petrolatum; c. 5-80% olive oil; d. 0.2-20% polysorbate 80; and e. 0.2-25% cyclosporine.
Claim 7
Dependent Claim
35 words
The pharmaceutical composition of claim 1, further comprising an effective amount of one or more immunosuppressants selected from the group consisting of: tacrolimus, mizoribine, azathioprine, cyclophosphamide, deoxyspergualin, didemnin B, methotrexate, thalidomide, rapamycin, or combinations thereof.
Claim 8
Dependent Claim
35 words
The pharmaceutical composition of claim 2, further comprising an effective amount of one or more immunosuppressants selected from the group consisting of: tacrolimus, mizoribine, azathioprine, cyclophosphamide, deoxyspergualin, didemnin B, methotrexate, thalidomide, rapamycin, or combinations thereof.
Claim 9
Dependent Claim
35 words
The pharmaceutical composition of claim 3, further comprising an effective amount of one or more immunosuppressants selected from the group consisting of: tacrolimus, mizoribine, azathioprine, cyclophosphamide, deoxyspergualin, didemnin B, methotrexate, thalidomide, rapamycin, or combinations thereof.
Claim 10
Dependent Claim
18 words
The pharmaceutical composition of claim 1, further comprising in approximate amounts by weight between 0.05-5% of hydrocortisone powder.
Claim 11
Dependent Claim
18 words
The pharmaceutical composition of claim 2, further comprising in approximate amounts by weight between 0.05-5% of hydrocortisone powder.
Claim 12
Dependent Claim
18 words
The pharmaceutical composition of claim 3, further comprising in approximate amounts by weight between 0.05-5% of hydrocortisone powder.
References Cited (Backward Citations)
US3288824A
Cited
US4108985A
Cited
US4210581A
Cited
US4117118A
Cited
US4289851A
Cited
US4220641A
Cited
US4388307A
Cited
US4288431A
Cited
US4396542A
Cited
US4554351A
Cited
US4384996A
Cited
US4857662A
Cited
US4639434A
Cited
US4553974A
Cited
US4681754A
Cited
US4771122A
Cited
US4703033A
Cited
US4649047A
Cited
US4677968A
Cited
JPS62201951A
Cited
US4764503A
Cited
EP0296122A2
Cited
GB2207678A
Cited
WO1989001772A1
Cited
US4839342A
Cited
DE3915617A1
Cited
US5124392A
Cited
FR2638089A1
Cited
US5059611A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-07-30 | 2000-01-29 | 2000-07-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-07-30 | 2004-01-29 | 2004-07-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-07-30 | 2008-01-29 | 2008-07-30 | $7700.00 | Window Closed / Lapsed |